Experts: Halt HIV Vaccine Trial; Say Resources Are Better Spent On More Promising Ones

Continuing a U.S. government-sponsored, large-scale trial of an HIV vaccine in Thailand is throwing good money after bad, a team of leading experts claims. "There is a very weak scientific rationale for going ahead and spending some $119 million and involving thousands of volunteers in this particular vaccine trial," says one of the letter's authors, Dr. Robert W. Doms, chairman of the department of microbiology at the University of Pennsylvania.

Back to news